Wednesday, November 13, 2019
- 9:00AM-10:30AM
-
Abstract Number: 2869
Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)- 9:00AM-10:30AM
-
Abstract Number: 2871
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)- 9:00AM-10:30AM
-
Abstract Number: 2885
An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)- 9:00AM-10:30AM
-
Abstract Number: 2873
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)- 9:00AM-10:30AM
-
Abstract Number: 2865
Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)- 9:00AM-10:30AM
-
Abstract Number: 2868
Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)- 9:00AM-10:30AM
-
Abstract Number: 2887
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)- 9:00AM-10:30AM
-
Abstract Number: 2859
Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
6W012: RA – Etiology & Pathogenesis II (2858–2863)- 9:00AM-10:30AM
-
Abstract Number: 2884
Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)- 9:00AM-10:30AM
-
Abstract Number: 2874
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)- 9:00AM-10:30AM
-
Abstract Number: 2891
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
6W017: Health Services Research II: Health Economics (2888–2893)- 9:00AM-10:30AM
-
Abstract Number: 2888
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
6W017: Health Services Research II: Health Economics (2888–2893)- 9:00AM-10:30AM
-
Abstract Number: 2881
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)